-
公开(公告)号：US20240350538A1
公开(公告)日：2024-10-24
申请号：US18763376
申请日：2024-07-03
申请人： MEDSENIC
发明人： Francois RIEGER , Simon RIEGER
摘要： The present disclosure relates to the use of an arsenic compound for treating a cytokine storm in a patient in need thereof.
-
公开(公告)号：US12090127B2
公开(公告)日：2024-09-17
申请号：US17584031
申请日：2022-01-25
发明人： Jingwu Xie
IPC分类号： A61P11/00 , A61K31/166 , A61K33/36 , A61P9/10 , A61B5/318 , A61B5/329 , A61B8/08 , A61K31/395 , A61K31/4365 , A61K31/437 , A61K31/4402 , A61K31/444 , A61K31/454 , A61K31/496 , A61K31/502 , A61K31/505 , A61K31/517 , A61K31/5377 , A61K31/58 , A61K39/395 , A61P1/16 , C07K16/18
CPC分类号： A61K31/166 , A61K33/36 , A61P9/10 , A61P11/00 , A61B5/318 , A61B5/329 , A61B8/0883 , A61K31/395 , A61K31/4365 , A61K31/437 , A61K31/4402 , A61K31/444 , A61K31/454 , A61K31/496 , A61K31/502 , A61K31/505 , A61K31/517 , A61K31/5377 , A61K31/58 , A61K39/3955 , A61P1/16 , C07K16/18
摘要： Methods of treating a valvular heart disease are provided. Methods for treating valvular heard disease include administering to a subject a therapeutically effective amount of at least one hedgehog pathway inhibitor. Also provided are methods for reducing fibrosis in a subject, which comprise administering to the subject a therapeutically effective amount of at least one hedgehog pathway inhibitor.
-
公开(公告)号：US11976300B2
公开(公告)日：2024-05-07
申请号：US17046383
申请日：2019-04-11
CPC分类号： C12N5/0641 , A61K9/146 , A61K33/36 , A61P7/00 , A61P7/02 , A61P7/06 , A61P35/02 , C12N2501/999 , C12N2506/1353
摘要： Disclosed is the use of a water-soluble realgar solid dispersion in the preparation of an erythroid differentiation inducer for bone marrow hematopoietic stem cells and/or bone marrow hematopoietic progenitor cells. The water-soluble realgar solid dispersion is prepared from raw materials comprising 1 part by weight of realgar, 1-20 parts by weight of a polymer, and 0-5 parts by weight of a surfactant. The water-soluble realgar solid dispersion can induce bone marrow hematopoietic stem and/or progenitor cells to be differentiated into red blood cells, promote the accumulation of red blood cells in bone marrow cells, effectively alleviate the decrease in the number of red blood cells caused by the suppression of the erythroid differentiation of bone marrow hematopoietic stem and/or progenitor cells, improve anemia caused by hematopoietic failure, and protect bone marrow cells from the killing effect.
-
4.发明公开公开(公告)号：US20230181632A1
公开(公告)日：2023-06-15
申请号：US17926480
申请日：2021-04-08
申请人： CHEMAS CO., LTD.
发明人： Ill Ju BAE , Seong Jin KIM , Kwang Soo LYOO , Kyung Min YANG , Zhaoyan WU , Min Jung SON , Kyoungwha PANG
摘要： Disclosed herein is a pharmaceutical composition comprising tetraarsenic hexoxide as an active ingredient. Having excellent antiviral activity against coronaviruses, the pharmaceutical composition can be advantageously applied to the prevention or treatment of coronavirus diseases.
-
公开(公告)号：US11643464B2
公开(公告)日：2023-05-09
申请号：US16728587
申请日：2019-12-27
IPC分类号： C07K16/28 , A61K39/395 , A61P27/02 , A61K45/06 , A61K31/404 , A61K31/7068 , A61K31/4155 , A61K33/36 , A61K39/00
CPC分类号： C07K16/2818 , A61K31/404 , A61K31/4155 , A61K31/7068 , A61K33/36 , A61K39/395 , A61K39/39541 , A61K45/06 , C07K16/2803 , C07K16/2827 , A61K2039/505 , A61K2039/507 , A61K2039/545 , A61K2039/572 , C07K2317/21 , C07K2317/24 , C07K2317/76 , A61K33/36 , A61K2300/00 , A61K31/404 , A61K2300/00 , A61K31/4155 , A61K2300/00 , A61K31/7068 , A61K2300/00
摘要： The present specification discloses a pharmaceutical composition comprising an active agent that causes reduction of the level of systemic immunosuppression in an individual for use in treating a disease, disorder, condition or injury of the CNS. The pharmaceutical composition is administered by a dosage regimen comprising at least one course of therapy, each course of therapy comprising in sequence a treatment session followed by an interval session of non-treatment.
-
6.发明申请公开(公告)号：US20190185563A1
公开(公告)日：2019-06-20
申请号：US16284081
申请日：2019-02-25
IPC分类号： C07K16/28 , A61K38/02 , A61K38/00 , A61K31/4155 , A61K38/16 , A61K38/18 , A61K38/20 , A61K38/14 , A61K45/06 , A61K31/404 , A61K39/395 , A61K33/36 , A61K31/7068
CPC分类号： C07K16/2803 , A61K31/404 , A61K31/4155 , A61K31/7068 , A61K33/36 , A61K38/00 , A61K38/005 , A61K38/02 , A61K38/14 , A61K38/168 , A61K38/18 , A61K38/208 , A61K39/395 , A61K39/39541 , A61K39/3955 , A61K45/06 , A61K2039/505 , A61K2039/507 , A61K2039/545 , A61K2039/57 , A61K2039/572 , A61K2121/00 , C07K16/2818 , C07K16/2827 , C07K2317/21 , C07K2317/24 , C07K2317/75 , C07K2317/76 , A61K2300/00
摘要： A pharmaceutical composition comprising an active agent that causes reduction of the level of systemic immunosuppression in an individual for use in treating a disease, disorder, condition or injury of the CNS that does not include the autoimmune neuroinflammatory disease, relapsing-remitting multiple sclerosis (RRMS), is provided. The pharmaceutical composition is for administration by a dosage regimen comprising at least two courses of therapy, each course of therapy comprising in sequence a treatment session followed by an interval session of non-treatment.
-
7.发明申请公开(公告)号：US20180189671A1
公开(公告)日：2018-07-05
申请号：US14787002
申请日：2014-04-25
发明人： Mohcine BENBIJJA , Pedro BOBE
CPC分类号： G06N10/00 , A61K33/36 , A61P17/00 , A61P17/06 , H01L21/568 , H01L23/564 , H01L23/66 , H01L24/80 , H01L2224/0231 , A61K2300/00
摘要： The invention concerns the field of human auto-immune and/or inflammatory diseases, and more specifically the use of arsenic compounds for the preparation of drugs intended for the treatment and/or prevention of skin injuries associated with auto-immune and/or inflammatory diseases in a human subject. The invention concerns an arsenic compound As2O5 for use in the treatment and/or prevention of skin injuries associated with auto-immune and/or inflammatory diseases in a human subject, a pharmaceutical composition comprising an arsenic compound As2O5, preferably for the treatment and/or prevention of skin injuries associated with auto-immune diseases in a human subject, and products containing an arsenic compound As2O5 and an arsenic compound As2O3 as a combination product for simultaneous, separated or time-spread use in the treatment and/or prevention of skin injuries associated with auto-immune diseases in a human subject.
-
公开(公告)号：US20180111999A1
公开(公告)日：2018-04-26
申请号：US15821678
申请日：2017-11-22
IPC分类号： C07K16/28 , A61K45/06 , A61K31/4155 , A61K31/7068 , A61K33/36 , A61K38/00 , A61K38/02 , A61K38/14 , A61K38/16 , A61K38/18 , A61K38/20 , A61K31/404 , A61K39/395 , A61K39/00
CPC分类号： C07K16/2803 , A61K31/404 , A61K31/4155 , A61K31/7068 , A61K33/36 , A61K38/00 , A61K38/005 , A61K38/02 , A61K38/14 , A61K38/168 , A61K38/18 , A61K38/208 , A61K39/395 , A61K39/39541 , A61K39/3955 , A61K45/06 , A61K2039/505 , A61K2039/507 , A61K2039/545 , A61K2039/57 , A61K2039/572 , A61K2121/00 , C07K16/2818 , C07K16/2827 , C07K2317/21 , C07K2317/24 , C07K2317/75 , C07K2317/76 , A61K2300/00
摘要： A pharmaceutical composition comprising an active agent that causes reduction of the level of systemic immunosuppression in an individual for use in treating a disease, disorder, condition or injury of the CNS that does not include the autoimmune neuroinflammatory disease, relapsing-remitting multiple sclerosis (RRMS), is provided. The pharmaceutical composition is for administration by a dosage regimen comprising at least two courses of therapy, each course of therapy comprising in sequence a treatment session followed by an interval session of non-treatment.
-
9.发明申请公开(公告)号：US20180111998A1
公开(公告)日：2018-04-26
申请号：US15821672
申请日：2017-11-22
IPC分类号： C07K16/28 , A61K45/06 , A61K31/4155 , A61K31/7068 , A61K33/36 , A61K38/00 , A61K38/14 , A61K38/16 , A61K38/18 , A61K31/404 , A61K39/395 , A61K38/20 , A61K39/00
CPC分类号： C07K16/2803 , A61K31/404 , A61K31/4155 , A61K31/7068 , A61K33/36 , A61K38/00 , A61K38/005 , A61K38/02 , A61K38/14 , A61K38/168 , A61K38/18 , A61K38/208 , A61K39/395 , A61K39/39541 , A61K39/3955 , A61K45/06 , A61K2039/505 , A61K2039/507 , A61K2039/545 , A61K2039/57 , A61K2039/572 , A61K2121/00 , C07K16/2818 , C07K16/2827 , C07K2317/21 , C07K2317/24 , C07K2317/75 , C07K2317/76 , A61K2300/00
摘要： A pharmaceutical composition comprising an active agent that causes reduction of the level of systemic immunosuppression in an individual for use in treating a disease, disorder, condition or injury of the CNS that does not include the autoimmune neuroinflammatory disease, relapsing-remitting multiple sclerosis (RRMS), is provided. The pharmaceutical composition is for administration by a dosage regimen comprising at least two courses of therapy, each course of therapy comprising in sequence a treatment session followed by an interval session.
-
公开(公告)号：US20170281566A1
公开(公告)日：2017-10-05
申请号：US15458636
申请日：2017-06-23
发明人： Filippo CICERI , Serena LUNARDI , Tamara MAES , Cristina MASCARÓ CRUSAT , Iñigo TIRAPU FERNÁNDEZ DE LA CUESTA
IPC分类号： A61K31/135 , A61K31/17 , A61K31/496 , A61K33/36 , A61K31/203 , A61K31/7068
CPC分类号： A61K31/015 , A61K31/12 , A61K31/135 , A61K31/17 , A61K31/19 , A61K31/203 , A61K31/282 , A61K31/337 , A61K31/4045 , A61K31/4745 , A61K31/475 , A61K31/496 , A61K31/519 , A61K31/555 , A61K31/64 , A61K31/704 , A61K31/7068 , A61K33/36 , A61P35/02 , A61K2300/00
摘要： The instant invention relates to combinations of the compound of formula (I) or pharmaceutically acceptable salts thereof with other active pharmaceutical ingredients pharmaceutical compositions comprising them, and their use as medicaments, particularly for the treatment of hematological malignancies.
-
-
-
-
-
-
-
-
-
搜索结果
332 条记录 (耗时 0.03 秒)
